Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Postmenopausal women with hormone receptor positive and negative Her2 tumours.
Before randomization, the patients will be stratified according to the center, positive nodes
(0 vs. 1-3 vs. ≥4), previous chemotherapy (yes vs no) and hormonal receptors status.